The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases

Tlatelpa-Romero, Beatriz; Cázares-Ordoñez, Verna; Oyarzábal, Luis F.; Vázquez-de-Lara, Luis G.

doi:10.3390/ijms24010326

Open AccessReview

The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases

by

Beatriz Tlatelpa-Romero

¹

,

Verna Cázares-Ordoñez

²,

Luis F. Oyarzábal

³ and

Luis G. Vázquez-de-Lara

^3,*

¹

School of Medicine, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico

²

Complejo Regional Nororiental, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico

³

Laboratorio de Medicina Experimental, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla 72420, Mexico

^*

Author to whom correspondence should be addressed.

Int. J. Mol. Sci. 2023, 24(1), 326; https://doi.org/10.3390/ijms24010326

Submission received: 10 November 2022 / Revised: 13 December 2022 / Accepted: 21 December 2022 / Published: 25 December 2022

(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Diffuse parenchymal lung diseases (DPLD) or Interstitial lung diseases (ILD) are a heterogeneous group of lung conditions with common characteristics that can progress to fibrosis. Within this group of pneumonias, idiopathic pulmonary fibrosis (IPF) is considered the most common. This disease has no known cause, is devastating and has no cure. Chronic lesion of alveolar type II (ATII) cells represents a key mechanism for the development of IPF. ATII cells are specialized in the biosynthesis and secretion of pulmonary surfactant (PS), a lipid-protein complex that reduces surface tension and minimizes breathing effort. Some differences in PS composition have been reported between patients with idiopathic pulmonary disease and healthy individuals, especially regarding some specific proteins in the PS; however, few reports have been conducted on the lipid components. This review focuses on the mechanisms by which phospholipids (PLs) could be involved in the development of the fibroproliferative response.

Keywords: pulmonary surfactant; phospholipids; lung fibrosis

Share and Cite

MDPI and ACS Style

Tlatelpa-Romero, B.; Cázares-Ordoñez, V.; Oyarzábal, L.F.; Vázquez-de-Lara, L.G. The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases. Int. J. Mol. Sci. 2023, 24, 326. https://doi.org/10.3390/ijms24010326

AMA Style

Tlatelpa-Romero B, Cázares-Ordoñez V, Oyarzábal LF, Vázquez-de-Lara LG. The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases. International Journal of Molecular Sciences. 2023; 24(1):326. https://doi.org/10.3390/ijms24010326

Chicago/Turabian Style

Tlatelpa-Romero, Beatriz, Verna Cázares-Ordoñez, Luis F. Oyarzábal, and Luis G. Vázquez-de-Lara. 2023. "The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases" International Journal of Molecular Sciences 24, no. 1: 326. https://doi.org/10.3390/ijms24010326

APA Style

Tlatelpa-Romero, B., Cázares-Ordoñez, V., Oyarzábal, L. F., & Vázquez-de-Lara, L. G. (2023). The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases. International Journal of Molecular Sciences, 24(1), 326. https://doi.org/10.3390/ijms24010326

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI